NCT01697293 - PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions

Breast AdenocarcinomaEstrogen Receptor PositiveHER2/Neu NegativeRecurrent Breast CarcinomaStage IIB Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast Cancer

Interventions

DRUG

Cyclophosphamide

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Paclitaxel

Given IV

PROCEDURE

Therapeutic Conventional Surgery

Undergo modified radical mastectomy, radical mastectomy, segmental mastectomy or lumpectomy with an axillary lymph node dissection or biopsy

DRUG

Triciribine Phosphate

Given IV

Trial Locations (2)

10461

Albert Einstein College of Medicine, The Bronx

33612

Moffitt Cancer Center, Tampa